Of the biomarker panels identified in this study (supplemental Table S16), we confirmed the known biomarkers of LC (i.e., ICAM2, LUM, and LGALS3BP) and HCC (i.e., SERPINA1, CLU, A2M, IGFBP2, VWF, FUCA1, and FBLN1) (supplemental Fig. S15A and supplemental Table S18). This evidence concerns the gene FBLN1 and laryngotracheoesophageal cleft.